Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2025; 17(2): 99612
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.99612
Hepatic artery infusion chemotherapy: A resurgence
Andrew Kai-Yip Fung, Kenneth Siu Ho Chok
Andrew Kai-Yip Fung, Kenneth Siu Ho Chok, Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong 999077, China
Author contributions: Fung AKY wrote the draft manuscript; Chok KSH approved the final manuscript; all of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kenneth Siu Ho Chok, FACS, FRCS (Ed), MBBS, MD, MS, Professor, Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong 999077, China. kennethchok@gmail.com
Received: July 26, 2024
Revised: October 31, 2024
Accepted: November 25, 2024
Published online: February 15, 2025
Processing time: 176 Days and 6.8 Hours
Core Tip

Core Tip: In the current landscape of accumulating knowledge of hepatocellular carcinoma (HCC), tumour biology and developments in systemic therapies, the management of advanced HCC has become increasingly complicated. For hepatic arterial infusion chemotherapy (HAIC) to be first-line treatment for advanced HCC, the morbidity of hepatic artery port insertion must be at a low level, the HAIC regimens must be standardised, the optimal combination treatment strategy with HAIC and the role of HAIC in Western populations must be evaluated. The combined roles of HAIC with immunotherapy and delivery of chemotherapeutic drug nanoparticles to HCC tumour cells represents an exciting research and therapeutic strategy for advanced HCC.